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Abstract
Background: Due to the arrival of multi-valent HPV vaccines, it is more and more important to have a better
understanding of the relationship between vaccination and screening programmes. This review aimed to: (1)
collect published evidence on the cost-effectiveness profile of different HPV prevention strategies and, in
particular, those combining vaccination with changes in screening practices; (2) explore the cost-effectiveness
of alternative preventive strategies based on screening and vaccination.
Methods: A systematic literature review was conducted in order to identify the relevant studies regarding the
cost-effectiveness of prevention strategies against HPV infection. Analysis comparing the modelling approaches
between studies was made along with an assessment of the magnitude of impact of several factors on the
cost-effectiveness of different screening strategies.
Results: A total of 18 papers were quantitatively summarised within the narrative. A high degree of heterogeneity was
found in terms of how HPV prevention strategies have been assessed in terms of their economic and epidemiological
impact, with variation in screening practice and valence of HPV vaccination found to have large implications in terms
of cost-effectiveness.
Conclusions: This review demonstrated synergies between screening and vaccination. New prevention strategies
involving multi-valence vaccination, HPV DNA test screening, delayed commencement and frequency of screening
could be implemented in the future. Strategies implemented in the future should be chosen with care, and informed
knowledge of the potential impact of all possible prevention strategies. Highlighted in this review is the difficulty
in assessing multiple strategies. Appropriate modelling techniques will need to be utilised to assess the most
cost-effective strategies.
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Background
Cervical cancer is now the fourth most common type of
cancer among women worldwide, and second most
common cause of death among women aged 15 to 44
[1]. Approximately 530,000 women develop cervical can-
cer worldwide annually, with 85% of cases in developing
countries [2, 3]. Cervical cancer is due to the human
papillomavirus (HPV), a family of viruses that infect
epithelial tissues of different sites [4–6]. Over 100 differ-
ent types of HPV have been identified. High risk types
(including 16, 18, 31 and 45) increase the risk of devel-
oping particular cancers. Low risk types 6 and 11 do not
cause cervical cancer but still affect the genital area,
causing 90% of genital warts. The virus also causes 90%
of anal cancers, 70–75% of vaginal and vulvar cancers,
and 60% of penile cancers [7, 8].
To prevent cervical cancers, screening programmes
have been introduced in many countries around the
world. These programmes have noticeably reduced the
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incidence of cervical cancer [9, 10]. Nevertheless, cervical
cancer continues to be a public health problem in Europe,
Australia, Canada and the USA [11–13]. In 2012, cervical
cancer was estimated to cause 12,977 deaths and there were
33,354 cases of cervical cancer in the EU. In 2015, it is esti-
mated in Canada, 1 in 152 Canadian women develop cer-
vical cancer during her life time and 1 in 475 will die for it
[11]. Similar trends follow in Australia and the USA.
The Pap smear is an essential cytological test and its
introduction has led to a high reduction in cervical
cancer incidence [14, 15]. Gibb and Martens, 2011,
report the incidence of cervical cancer to have reduced
by nearly 70% between 1955 and the mid-1980s [16].
Despite its success, the test is limited by low sensitivity,
with approximately 50% of women with lesions classi-
fied as negative, and it does not detect adenocarcin-
oma. The low sensitivity of the test requires it to be
repeated on a regular basis (every year or every 3–5
years depending on the programme) [17]. In addition,
its use has plateaued or reduced in some countries
leading to an HPV incidence increase [17–19].
HPV DNA testing is a recent development in the
management of HPV and is much more sensitive when
compared to the Pap smear [20]. The implementation of
HPV DNA testing is still on-going in developing countries.
Other biomarkers could enable a fully molecular-based
approach to screening in the future.
Whereas screening detects diseases at an early stage
(precancerous lesions) leading the treatment of these
lesions prior to cancer development, vaccination prevents
HPV-related disease and the burden related to treatment.
HPV vaccination has been implemented in Europe
since 2007, in addition to the existing cervical cancer
screening programmes. Available vaccines at that time
aimed to prevent ~70% of cervical cancers and ~50% of
precancerous lesions, related to HPV 16 & 18 HPV
[21, 22]. The new generation vaccine (GARDASIL 9) aims
to prevent ~ 90% of cervical cancers and ~80% of precan-
cerous lesions, related to HPV 16,18,31,33,45,52,58 [23].
The vaccine was approved by the Food and Drug Ad-
ministration (FDA) in 2014 for use in girls aged 9 to 26
and males aged 9 to 15. Similarly, in 2015, the Commit-
tee for Medicinal Products for Human Use (CHMP) rec-
ommended the vaccine for use in boys and girls from
9 years of age to protect against cervical, vulvar, vaginal
and anal cancers, and pre-malignant cervical, vulvar, va-
ginal, and anal lesions and external genital warts [13].
This vaccine has the potential to further reduce the inci-
dence of pre-cancerous lesions and cervical cancers,
complementary to screening [24].
Context and objectives
The vaccination of successive cohort of girls has the po-
tential to reduce the average lifetime risk of developing
cervical abnormalities and cervical cancer in the popula-
tion; hence, the predictive value of cytology will decrease
as well as the effectiveness of most screening modalities
[25]. Therefore, existing screening practices will most
likely evolve with regard to their frequency and strategy.
Several systematic reviews, including the recent review
by Mendes et al., 2015 [25], have assessed the cost-
effectiveness of different screening strategies. Other
studies have evaluated the cost-effectiveness of HPV vac-
cination strategies and concluded that vaccination added
to the existing screening programme was a cost-effective
strategy [26]. However, no study has reviewed model-
based cost-effectiveness studies of a potential change of
screening practice in conjunction with vaccination with
analysis of the sensitivity of specific parameters. In the
context of the arrival of multi-valent HPV vaccines, it is
more and more important to have a better understand-
ing of the relationship between vaccination and screen-
ing programmes.
The current study aimed to review the published
literature to:
 Collect published evidence on the cost-effectiveness
profile of different HPV prevention strategies and, in
particular, those combining vaccination with
changes in screening practices
 Explore the cost-effectiveness of alternative
preventive strategies based on screening and
vaccination.
The study focussed on key European markets (Austria,
Belgium, Czech Republic, Denmark, Finland, France,
Germany, Greece, Ireland, Italy, the Netherlands,
Poland, Portugal, Slovenia, Spain, Sweden, the UK,
Switzerland, Norway), Australia, Canada and the USA.
Methods
A systematic literature review was conducted in order to
identify the relevant studies regarding the cost-
effectiveness of prevention strategies against HPV
infection. The study question was formalised accord-
ing to the PICOS framework (see Appendix 1 and
Appendix 2).
We searched the following electronic databases for
studies published up to April 2014: MEDLINE and
MEDLINE-IN-PROCESS (via Ovid, on 15th April
2014), on EMBASE (via embase.com, on 15th April
2014), and the NHS Economic Evaluation database
(via cochrane.org on 15th April 2014). Search terms
are included in Appendix 1. Following search
completion, studies were screened and irrelevant
publications excluded based on the pre-defined
criteria (Appendix 1).
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We included original research articles that met the
following criteria:
1. Cost-effectiveness analyses based on mathematical
modelling
2. Presentation of a health economic endpoint (quality-
adjusted life-year or cost-effectiveness ratio) and
clinical outcomes (cancers/cases avoided)
After running the searches on the electronic databases,
the citations were screened by two independent re-
viewers, with study selection based on the pre-specified
inclusion/exclusion criteria in Appendix 1. Studies of pa-
tients vaccinated against HPV infection, and with a
cervical screening strategy were included. The three
comparators included were vaccination against HPV in-
fection only, an alternative cervical screening strategy
only or a combination of both. The study type of interest
was restricted to cost-effectiveness analyses and out-
comes assessed were health economic or clinical out-
comes. The exclusion criteria are detailed in Table 5 in
Appendix 1. The publication selection was based on an
initial review of titles and abstracts and a second review
of full-texts. Quality check was conducted by the second
independent reviewer and any discrepancies between the
two reviewers were resolved through discussion.
Upon the completion of publication selection, relevant
data were extracted according to a pre-specified
template, which included authors, year of publication,
country, period of analysis, mathematical model used,
vaccine, price per dose and schedule, discounted rate,
population, age of vaccination and catch-up, comparator,
clinical outcomes considered, vaccine efficacy, duration
of protection, assumptions on vaccination coverage,
screening status, sensitivity analysis conducted, eco-
nomic outcomes (cost per quality-adjusted life-year
(QALY) and cost per life-year gained (LYG)). Data was
then quantitatively summarised within a narrative
review. Different scenarios on screening strategy and
frequency from included studies were synthesized and
plotted against changes in cost and QALY.
Results
Overview
A total of 1,188 papers were identified following removal
of duplicates. Of the papers screened 115 were deemed
eligible for full-text review. Following exclusion, a total
of 18 papers were quantitatively summarised within the
narrative review using the preferred reporting items for
systematic reviews and meta-analyses (PRISMA) dia-
gram. (see Fig. 1). Of the studies included eight focused
on the US [27–34], 3 on the Netherlands [35–37], 1 on
Italy [38], 1 on Australia [39], Canada [40], France [41],
Norway [42], Spain [43], and Eastern Europe [44],
respectively (Table 6 in Appendix 2).
Analysis comparing the modelling approaches between
studies was made along with an assessment of the mag-
nitude of impact of several factors on the cost-
effectiveness of different screening strategies. Strategies
which were only assessed as part of sensitivity analyses
were also compared. The impacts of several factors on
the cost-effectiveness of the HPV prevention strategies
were assessed such as modelling approach, prevention
strategies assessed, screening technique, screening fre-
quency, age at first vaccination, screening coverage and
compliance, number of vaccine valences and cross-
protection, vaccine efficacy, efficacy waning effect and
vaccine cost.
Vaccination strategies
Vaccination programmes
Vaccination strategies varied considerably in terms of
cost-effectiveness both within and between studies
through both age of vaccination and number of doses
received, as well as booster (Tables 1 and 2).
Sixteen studies focused on the vaccination of pre-
adolescent girls; the remaining 2 [30, 40] on catch-up
programmes.
Vaccination coverage was seen to differ across studies
from 70 to 100% in base case, and varied in sensitivity
analyses.
Vaccine efficacy
Bivalent vaccine efficacy was reported to be greater than
75%, 90% and 95% versus HPV types 16/18 in 2 [27, 38],
8 [27, 29, 32, 35–37, 40, 43] and 5 [31, 33, 34, 39, 41]
studies respectively, under base case. Vaccine protection
duration was reported as lifelong following completion
of the HPV vaccination programme in all but 2 [27, 28]
studies, reporting duration as ten years.
Cross-protection against other high-risk HPV types
was considered in 7 [30, 31, 33, 34, 39, 41] studies.
Vaccine valence
The majority of studies (17/18) focused on a bivalent
(HPV16/18) or a quadrivalent vaccine (HPV6/11/16/18)
(Table 3). Only one study [37] explored introduction of
modelling vaccine valences of 5 to 13 (theoretical exercise
only). Coupe et al., 2012 [35], concluded that an identical
screening programme for vaccinated and unvaccinated
women was no longer defensible if vaccinated women
were protected against many high-risk HPV types by
means of effective broad-spectrum vaccination. An
increase in duration of screening interval was seen to
lower costs but benefits as well. Broader vaccinations with
valences from 5 to 13 high-risk HPV types were modelled;
a 5-valent vaccine was seen to be least costly but offered
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fewest QALY gains, whilst a 13-valent vaccine was seen to
offer greatest benefits but at greatest cost. The greater the
time interval between screenings the greater the QALY
gain from a vaccine of greater valence.
Vaccine cost
Cost of vaccination was another variable between studies
with bivalent and quadrivalent 3-dose vaccine cost
varying from €147.00–402.00 and €264.00–360.00,
respectively.
Costs were seen to have an important effect on the ICER
of optimal strategies and significantly affect the cost-
effectiveness result of vaccination strategies. Demarteau et
al., 2011 [41] reported a change in vaccine cost to signifi-
cantly alter the ICER for vaccination of 12 year old girls.
Taira et al., 2004 [32] and Kulasingam et al., 2007 [39] re-
ported a change in vaccine cost to have a significant impact
on the ICER, with a decrease in cost seen to have greater ef-
fect than an increase.
Overview of screening approaches considered
Various HPV prevention strategies were assessed in the
included studies (Table 7 in Appendix 2). All studies in-
cluded screening of women for HPV infection within
their models. In total there were five different screening
strategies:
 Pap smear test alone (conventional cytology or
liquid-based cytology): detection of cervical
precancerous lesions
 HPV DNA test alone: detection of HPV infections
and HPV types
 Pap test + HPV DNA triage for Pap positive patient
 HPV DNA test + Pap triage for HPV DNA positive
patient
 Combined Pap test + HPV DNA test.
Pap test was included as a primary screening meas-
ure in all studies including screening, with varying
combinations of the inclusion of HPV DNA testing
and/or cytological testing as an additional screening
measure, or triage.
Changes to existing cytology-based screening alongside
vaccination
Liquid-based cytology
As a primary screening strategy, liquid-based cytology
was compared to classical cytology in 1 study [29]. Com-
paring classical cytology and liquid-based cytology in
Fig. 1 PRISMA diagram
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Table 1 Vaccination strategies
Kulasingam 2003 [27] Sanders 2003 [28] Goldie 2004 [29] Taira 2004 [32] Kulasingam 2007 [39]
Vaccine considered Bivalent Bivalent Bivalent Bivalent Bivalent
Age of vaccination (y) 12 (12–19) 12 (12–15) 12 (12–15) 12 12
Catch-up - - - - -
Booster 0 (1) 10y (3y-lifetime) - (Yes) 10y - (1)
Vaccine price
(3 doses)
$200 ($100–$600) $300
($100–$500)
$377
($188–$565)
$300 ($100–$400) AUS$345 ($300–$450)
Coverage 100%
(50–100%)
- 100%
(50–100%)
- 80% (70–90%)
Compliance 100% 70% (30–100%) 100% - -
Efficacy 90%
(25–100%)
75% (0–100%) 90%
(50–100%)
90% (10–90%) 100% (93–100%)
Protection duration (y) 10 (2–30) 10 - - Lifetime
Waning effect - - No
(5,10,15,20y)
Yes (No) -
Herd Immunity - - - - Considered in SA
Goldhaber-Fiebert
2008 [33]
Kim 2008 [31] Coupe, de Melker
2009 [35]
Coupe, van Ginkel 2009 [36] Kim 2009 [30]
Vaccine considered Bivalent Bi/Quadrivalent Bivalent Bivalent Bi/Quadrivalent
Age of vaccination 9 12 12 12 12
Catch-up In SA 18,21,26y - - -
Booster - 10y - 30y in SA -
Vaccine price
(3 doses)
$402 ($300–$900) $360 € 375 € 375 $360
Coverage 25%, 75%, and 100% 75% 100% 85% -
Compliance - - 100% - 100%
Efficacy 100% (75%) 100% 95% 95% (85-90-98%) Infection: ♀ 100%/♂ 85%
Disease: ♀ 100%/♂ 90%
Protection duration Lifetime (15y) Lifetime Lifetime Lifetime Lifetime
Waning effect - 10 years 10 or 20 years - (exponential decrease in
efficacy of 50% during each
following 20 years 10y, or
5 years)
-
Herd Immunity - (Yes) - - - Yes
Kim, Ortendahl
2009 [34]
Accetta 2010 [38] Diaz 2010 [43] Demarteau 2011 [41] Burger 2012 [42]
Vaccine considered Bivalent Bivalent Bivalent Bivalent Quadrivalent
Age of vaccination 35 11 11 12 12
Catch-up - Yes - up to 25y in SA -
Booster -(Yes) -(10–20y) No - (1) -
Vaccine price
(3 doses)
$402
($250–$750)
€ 309.23 (€90) € 312 (€150–€600) € 401 (€321–€482) $489
Coverage Not clear 100% 90% (50–100%) - -
Compliance 100% - - - -
Efficacy 100% (70%) 75.90% (95%) 100% (60–100%) 98% (78–100%) -
Protection duration Lifetime - Lifetime (10y) - -
Waning effect -(5–10y) - - -(15–20y) -
Herd Immunity - - - - -
Coupe 2012 [37] Tully 2012 [40] Berkhof 2013 [44]
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vaccinated women, Goldie et al., 2004 reported a very
small increase in QALYs and a marginal raise (between
0.5% and 1.2%) in the reduction in cancer risk with
major increase in costs.
Changes in screening interval
All studies except one [43] modelled the effect on cost-
effectiveness of variation in screening interval in vacci-
nated persons. Clinical benefit was seen when durations
between screenings were reduced; however, this came at
an economic cost. By combining vaccination with
screening, the screening interval could be increased with
only a marginal impact on benefits and a large reduction
in costs. Introduction of a vaccine of greater valence was
shown to offset negative effects of decreasing screening
frequency (see Fig. 2) [37].
Delaying screening commencement
Five studies investigated the effect of delaying the age of
screening commencement (from ages of 18–35 years
old) [27, 29, 33, 35, 39, 40]. Goldie et al., 2004 [29]
reported that delaying the age of screening commence-
ment from 21 to 25 years was associated with cost-sav-
ings. Delaying the screening age from 30 to 35 was
reported not to be cost-effective by Coupe de Melker et
al., 2009 and the same trend was reported in Tully et al.,
2012 [35, 40].
Compliance to screening
One study [36] reported the impact of compliance to
screening on HPV prevention strategy. A 10% decrease
in attendance per screening round for vaccinated women
compared to non-vaccinated women, resulted in a
marginal impact on cost-effectiveness results.
HPV DNA test
A strategy of HPV DNA testing was assessed in 5 studies
[33, 35, 37, 38, 44] and a combined screening strategy
(cytology and HPV DNA testing) in 2 studies [34, 43].
HPV DNA testing triage was assessed in 7 studies [33–
35, 38, 42, 43].
Combined screening strategies in combination with
vaccination were seen to offer large clinical benefits, at
little extra cost in studies including non-conventional
techniques when compared to strategies of vaccin-
ation only.
After the introduction of HPV vaccination, screening
still needed to be continued, and strategies that incorpo-
rated HPV testing were more effective and cost-effective
than those with cytology alone [43]. strategies involving
HPV DNA testing and subsequent cytology triage were
associated with a greater QALY gain than a strategy
involving vice versa; and, interestingly a strategies of
HPV DNA testing alone offered greater QALY gain than
those of cytological screening followed by HPV DNA
test triage (see Fig. 2).
Modelling methods
Three modelling approaches were used for assessment
in the included studies: 9 studies reported using a stand-
ard Markov model [27–29, 35, 36, 38, 39, 41]; 9 studies
were based on a standard dynamic model [31–34, 37,
40, 42–44]; and 1 study [30] reported using a two-
part model.
Discussion
Key findings from literature review
Cervical cancer screening is one of the cornerstones of
cervical cancer prevention in association with HPV vac-
cination. This study explored the cost-effectiveness of
alternative HPV prevention strategies that combine
Table 1 Vaccination strategies (Continued)
Vaccine considered Bivalent &
multivalent
Bivalent Bivalent
Age of vaccination Not Clear 12 12
Catch-up - 18y in SA -
Booster - 25y in SA -
Vaccine price
(3 doses)
- $270 CAD $300
Coverage 100% 80% 70%
Compliance - - -
Efficacy 95% >90% -
Protection duration Lifetime Lifetime -
Waning effect -(Yes) Considered in SA
(unavailable)
-
Herd Immunity - Accounted -
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Table 2 Screening strategies
Kulasingam 2003 [27] Sanders 2003 [28] Goldie 2004 [29] Taira 2004 [32] Kulasingam
2007 [39]
Primary screening CC CC CC/LBC CC CC
Compliance 100% (50–100%) 71% (60–80%) 100% - By age
Triage CC - HPV DNA - -
Cytology
Sens/Spe 0.556(0.51–0.95)/
0.957(0.80–0.97)
0.51(0.40–0.80)/
0.97(0.95–0.98)
0.66(0.34–0.86)/
0.97(0.88–0.99)
- 0.80(0.48–0.80)/
0.95(0.90–0.99)
Price $45 ($61–$75) $81($61–$101) $15–$51
($12–75)
$58($29–$86)
HPV DNA
Sens/Spe - - - - -
Price $49 ($30–$200)
Goldhaber-Fiebert 2008 [33] Kim 2008 [31] Coupe, de Melker
2009 [35]
Coupe, van Ginkel
2009 [36]
Kim 2009 [30]
Primary screening CC/HPV DNA CC CC/HPV DNA CC CC
Compliance - - 80% 80% (20/70%) -
Triage HPV DNA/CC HPV DNA (3y) HPV DNA/CC - HPV DNA
Cytology
Sens/Spe 0.8(0.186–0.99)/0.95(0.87–0.996) - - - -
Price $30($6–$87)
HPV DNA
Sens/Spe 0.83(0.70–0.85) / 0.93(0.79–0.94) - 0.94/1 - -
Price $55($14–$217)
Kim, Ortendahl 2009 [34] Accetta 2010 [38] Diaz 2010 [43] Demarteau 2011 [41] Burger 2012 [42]
Primary screening CC/Combined CC/HPV DNA CC/Combined CC CC
Compliance 53% 1y, 17% 2y, 11% 3y, 15% 5y 70.90% - 60% 3y (48%,1y-72%,5y) 100%
Triage HPV DNA HPV DNA/CC HPV DNA - HPV DNA
Cytology
Sens/Spe 0.8/0.95 0.8/0.95 0.8/0.95 0.58–0.61 (0.46–0.73) 0.8/0.95
Price
HPV DNA
Sens/Spe 0.93/0.93 0.96/0.94 0.88/0.93 - 1/1
Price
Coupe 2012 [37] Tully 2012 [40] Berkhof 2013 [44]
Primary screening CC/HPV DNA CC CC/HPV DNA
Compliance 80% (40%) - -
Triage -/CC - -
Cytology
Sens/Spe - 0.58–0.85/0.962–0.974 -
Price €52.80
HPV DNA
Sens/Spe 0.94/0.97 - -/1
Price €65.6
CC refers to the Pap smear test
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screening with vaccination, drawing on 18 publications
in order to inform and improve knowledge of the poten-
tial impact of the next generation of HPV vaccines.
Among the strategies modelled, HPV DNA testing
followed by cytological triage of HPV positive women in
combination with HPV vaccination was found to be the
optimal strategy, with a comparable cost to other screen-
ing strategies and also a greater QALY gain. An increas-
ing vaccine valence counterbalanced the detrimental
effects of delayed and less frequent screening (Fig. 2).
Strategies with shorter screening intervals were more
costly and offered limited added benefit compared to
those with longer intervals.
In our review, only 1 study considered changes in
screening programs in a context of vaccines that covered
than 2 oncogenic HPV types (HPV16/18), with the
change in benefits gained from a vaccine of increasing
valence offsetting the change in costs associated with a
shorter interval between screenings [37]. A nonavalent
vaccine, with protection against 5 additional HPV onco-
genic types, and 9 HPV types in total, is expected to pre-
vent an even broader spectrum of HPV diseases and in
particular to cover from 70% to 90% of cervical cancers.
In light of the introduction of this new HPV vaccine to
the European markets, a shift in the HPV prevention
paradigm is expected, especially in country with high
coverage rate.
Simms et al., recently concluded that countries with
high vaccination coverage with HPV9 such as
Australia and England will require less intensive
screening [45]. At this level of protection, the role of
screening in vaccinated women will need to be re-
examined, and possibly reduced to 3 tests in a lifetime,
for example, ages 30, 40, and 60 years; however, this
will need to be verified in large studies using a HPV
screening test. [46] It is possible that a single screen-
ing in combination with HPV9 will produce equivalent
results as compared to Gardasil® in combination with
3–4 screenings [47].
One of the main limitations of this review was to ex-
clude models that estimated clinical outcomes alone, in-
stead focusing on economic models estimating clinical
and economical outcomes. Nevertheless, economical con-
sideration are rarely disconnected from clinical outcomes
in the decision making process. Economic models which
make use of the best available data can provide an assess-
ment of the long-term impact of vaccination and screen-
ing against HPV and guide decision makers into making a
better informed decision regarding which prevention
strategy to employ.
The above graph presents a plot of the incremental
costs and QALYs of each vaccination strategy with
increasing valence. The impact in terms of increas-
ing costs and QALYS on cost-effectiveness results of
decreasing the screening interval for each vaccin-
ation from no screening to annual screening can
then be seen by moving rightwards on each curve.
From the above figure, increasing valence is shown
to generate additional health benefits at with cost
savings versus decreasing the screening interval,
which is associated with sharp cost increases for the
additional health benefit generated.
Methodological challenges
Although the conclusions of our review may appear
limited because of the time span (until April 2014)
Fig. 2 Synthesised results of the systematic literature review. This figure is not to scale, it displays the trend
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and the fact that they do not consider the new nonava-
lent vaccine, they provide important insights into the
methodological challenges in assessing vaccination
and screening. Firstly, the choice of the model can
limit the scope of the analysis. Most of the models
presented in our review are static Markov models and
considered only vaccinated women. These models
have the advantages of assessing various screening
components (different types of screening, change in
screening interval, switching age for protocol allowing
different tests in younger and older women). Static
Markov models cannot adequately take into account
herd immunity, age distribution shifts, waning ef-
fects, nor do they provide a population-based per-
spective, therefore do not perfectly reflect disease
transmission. In many countries, policy makers will
have to consider an existing mix of vaccinated and
unvaccinated women.
Static models cannot adequately take into account
herd immunity nor age distribution shifts. Risk of
infection in susceptible individuals is constant in
static models, while in dynamic models, it is a func-
tion of the proportion of the population infected
(which changes over time). Hence, when intervention
uptake is very low (e.g., low vaccine coverage), is
targeted at groups that do not have an impact on
overall transmission, or does not prevent circulation
of the pathogen, static and dynamic models produce
similar results.
To assess the change of screening in unvaccinated
women, a cohort-based model can be used. Naber et
al., 2016 [48] (not included in this review due to
timing of publication) recently used an indirect
method based on a cohort based-model to investi-
gate at which level of herd immunity screening
should be optimised for unvaccinated women. Once
herd immunity reached 50%, the authors suggested
that reducing screening intensity in both vaccinated
and unvaccinated women may be considered, given
screening intensity based on pre-vaccination risk
levels becomes cost-ineffective [48]. To consider a
population-based perspective, 2 types of population-
based model co-exist: compartmental dynamic and
individual-based dynamic models [31]. Including de-
tailed features of screening such as different test in
younger and older women in a compartmental dy-
namic model is not easy. Individual-based models
are by definition more flexible and appear to offer a
better combination in terms of prevention strategies
modelled and population perspective.
Specific attention needs to be considered to evaluate
cervical screening technologies. This was not in the
scope of our review but Simonella et al. (2015) [49]
demonstrated that the models of organised screening
in the evaluation of the cost-effectiveness of HPV vac-
cination varied in quality. With respect to some im-
portant areas of screening (abnormal Pap smear
management, diagnostic follow up and management of
CIN), models were inconsistent in structure and, in
some cases, very simplified. They concluded that
models of HPV vaccination can be improved by fur-
ther attention to the ‘background’ modelling of sec-
ondary prevention via cervical screening.
Another difficulty in assessing the best preventive
strategies is the number of strategies that can poten-
tially be assessed, and this can quickly become huge
if different age intervals, different tests and different
algorithms are evaluated. Sander et al. 2016 recently
considered 900 combinations of vaccination and
screening strategies [50]. The most cost-effective
option may depend on the initial set of options con-
sidered, with the potential for the comparison of
each strategy to a common comparator leading to a
sub-optimal decision. In this circumstance it is
important to develop an efficiency frontier, removing
dominated strategies and those subject to extended
dominance; this will lead to the strategy with the
highest ICER below the cost-effectiveness threshold
being selected.
Regarding the long term impact of HPV vaccines,
the scientific community acknowledges that protec-
tion against HPV associated diseases related to vac-
cine types has been demonstrated for at least
10 years and that and long term follow up studies
does not show any decrease in efficacy over time
[51]. In addition, recent WHO guidance on cervical
cancer the duration and strength of effectiveness of
cross protection is still to be demonstrated [52].
Therefore scenarios with cross-protection and or
with a low duration of protection could be consid-
ered as less relevant and were therefore omitted
from this analysis.
Next steps
A single programme of vaccination and screening will
need to be deliberated when considering further re-
duction of the cervical cancer burden [17, 53]. Add-
itionally, introduction of HPV DNA testing in several
European countries is seen as having the potential to
alter the cervical cancer screening paradigm. There is
still considerable uncertainty around the direction of
this change and further research is needed in order
to assess the impact on the cost-effectiveness profile
of HPV prevention strategies. It will be important to
obtain high coverage through vaccination, meaning
screening will be needed less regularly; however, a
challenge will remain to accurately identify those who
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have been vaccinated, as this will occur prior to the
need for screening.
Some governments, such as in Australia, have already
adapted their screening programme, accelerating the im-
plementation of HPV DNA testing, due to the success of
vaccination [53]. Moreover, the availability of a nonava-
lent HPV vaccine will enable a complete review of
current cervical cancer prevention strategies, in both a
primary and secondary setting, offering the opportunity
for a more efficient and affordable approach.
Existing analyses in this article, and the recent ones
not included in our review [48, 50], focus on a 3-
doses HPV vaccine and/or a vaccine that protects
against 70% of cervical cancer and are probably obso-
lete [48]. New analyses considering changes in screen-
ing programs in a context of a nonavalent vaccine
that protects against 90% of cervical cancers and
using more realistic vaccination programmes in term
of costs (2 dose schedule instead of 3 dose) and
coverage rate (vaccinated and unvaccinated popula-
tion) are needed.
As referred to by Mendes et al., 2015 the choice of
optimum cervical cancer screening strategies will be
highly complex due to the number of criteria to
consider from a policy viewpoint and especially rele-
vant in countries with high vaccination coverage
rates [54].
Further research on country-specific data for HPV
vaccination and screening as well is the corresponding
economic impact should be conducted to generate
evidence which can assist policy-makers in finding a
more systematic and tailored approaches to HPV
prevention.
Conclusion
This review has highlighted how HPV prevention strat-
egies have been demonstrated to show both an eco-
nomic and epidemiological impact. The arrival of a new
HPV vaccine has the potential to dramatically alter the
epidemiological outlook of HPV, and, as a consequence,
current screening programmes may need to be re-
thought. The need to re-assess current prevention pro-
grammes is increasingly highlighted [55].
This review has demonstrated synergies between
screening and vaccination. New prevention strategies in-
volving multi-valence vaccination, HPV DNA test
screening, delayed commencement and frequency of
screening could be implemented in the future.
HPV prevention strategies implemented in the
future should be chosen with care, and informed
knowledge of the potential impact of all possible pre-
vention strategies. Availability of a nonavalent vaccine
will allow a complete review of current strategies,
offering an opportunity for a more efficient and
affordable approach to HPV prevention.
Also highlighted in this review is the difficulty in
assessing the interaction between screening and vac-
cination and in assessing multiple strategies in gen-
eral. Appropriate modelling techniques will need to
be utilised to assess the most cost-effective strategies,
with recommendations made based on analysis of effi-
ciency frontiers and similar techniques.
Appendix 1
Systematic review search methods
Table 4 PICOS framework
PICOS Definition
Population All individuals
Intervention Vaccination against HPV infection, with a cervical
screening strategy
Comparators One of the following three scenarios:
- Vaccination against HPV infection, with an
alternative cervical screening strategy
- Vaccination against HPV infection only
- An alternative cervical screening strategy only
Outcomes Health economic endpoint (with a focus on the
cost-effectiveness result (quality-adjusted life-year,
cost-effectiveness ratio) and clinical outcomes
(cancers/cases avoided)
Study types Cost-effectiveness analyses
Table 5 Exclusion criteria
Exclusion criteria Notes
Null entries No information is reported in title
and abstract fields
Duplicates Duplicate of an existing entry
Not in the language of interest English only
Abstract that is reported
elsewhere
A conference abstract with the
content reported in another
publication
Not study type of interest Not a cost-effectiveness analysis
Not HPV vaccination Not including an arm of HPV
vaccination ± screening
Not the country of interest Countries of interest include: Austria,
Belgium, Switzerland, Czech Republic,
Germany, Denmark,
Spain, Finland, France, Greece, Ireland,
Italy, the Netherlands, Norway, Poland,
Portugal, Sweden, Slovenia, and the UK,
the US, Canada and Australia
No outcome of interest Health economic endpoints
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Table 7 Prevention strategies
Kulasingam 2003 [27] Sanders 2003 [28] Goldie 2004 [29] Taira 2004 [32] Kulasingam 2007 [39]
Strategy assessed .No Intervention
.Vaccination only (12 F)
.Cytology 18 F - 5y
. Cytology 18 F - 3y
. Cytology 18 F - 2y
. Cytology 18 F - 1y
.Vaccination (12 F) +
Cytology 30 F - 5y
.Vaccination (12 F) +
Cytology 18 F - 5y
.Vaccination (12 F) +
Cytology 26 F - 3y
.Vaccination (12 F) +
Cytology 18 F - 3y
.Vaccination (12 F) +
Cytology 24 F - 2y
.Vaccination (12 F) +
Cytology 18 F - 2y
.Vaccination (12 F) +
Cytology 22 F - 1y
.Vaccination (12 F) +
Cytology 18 F - 1y
.Cytology (16 F) - 2y
(.Vaccination (12 F) +
Cytology (16 F) - 1y)
.Vaccination (12 F) +
Cytology (16 F) - 2y
(.Vaccination (12 F) +
Cytology (16 F) - 3y
.Vaccination (12 F) +
Cytology (16 F) - 4y
.Vaccination (12 F) +
Cytology (16 F) - 5y)
.No intervention
.Cytology 35 F - 5y
.Cytology 30 F - 5y
.Cytology 25 F - 5y
.Vaccination (12 F) +
Cytology 35 F - 5y
.Vaccination (12 F) +
Cytology 30 F - 5y
.Vaccination (12 F) +
Cytology 25 F - 5y
.Vaccination (12 F) +
Cytology 21 F - 5y
.Vaccination (12 F) +
Cytology 25 F - 3y
.Vaccination (12 F) +
Cytology 21 F - 3y
.Vaccination (12 F) +
Cytology 21 F - 2y
.Vaccination (12 F) +
Cytology 18 F - 2y
.Vaccination (12 F) +
Cytology LBC 18 F - 2y
.Vaccination (12 F) +
Cytology 18 F - 1y
.Vaccination (12 F) +
Cytology LBC 18 F - 1y
. Cytology ?F - 2y
(.Vaccination (12 F) +
Cytology ?F - 4y
.Vaccination (12 F) +
Cytology ?F - 3y))
.Vaccination (12 F) +
Cytology ?F - 2y
(.Vaccination (12 F) +
Cytology ?F - 1y)
.No intervention
.Vaccination only (12 F)
.Cytology 18-21 F - 2y
.Vaccination (12 F) +
Cytology 18-21 F - 2y
.Vaccination (12 F) +
Cytology 18-21 F - 3y
.Vaccination (12 F) +
Cytology 25 F - 3y
Results ICER/life year gained,
reduction in cervical cancer
incidence and mortality
ICER/QALY gained,
reduction in cervical
cancer incidence
and mortality
ICER/QALY gained, reduction
in lifetime risk of cervical
cancer
ICER/QALY gained ICER/life year gained
Goldhaber-Fiebert 2008 [33] Kim 2008 [31] Coupe, de Melker
2009 [35]
Coupe, van Ginkel
2009 [36]
Kim 2009 [30]
Strategy assessed .No intervention
.Vaccination only (9 F)
.Cytology 18 F,21 F,25
F – 5y,3y,2y,1y + HPV triage
(Switch 25y,30y,35y)
.HPV 18 F - 1y + Cytology
triage
.Vaccination (9 F) +
Cytology 18 F,21 F,25
F – 5y,3y,2y,1y + HPV triage
(Switch none, 25y,30y,35y)
.Vaccination (9 F) + HPV 25
F - 3y + Cytology triage
.Cytology 20 F - 1y
.Cytology 20 F - 2y
.Cytology 20 F - 3y +
HPV Triage
.Vaccination (12 F) +
Cytology 20 F - 1y
.Vaccination (12 F) +
Cytology 20 F - 2y
.Vaccination (12 F) +
Cytology 20 F - 3y +
HPV Triage
.Vaccination only (12 F)
.Cytology 30 F,35 F - 4,5,6,7
rounds
.Cytology + HPV triage 30
F,35 F - 4,5,6,7 rounds
.HPV + Cytology triage 30
F,35 F - 4,5,6,7 rounds
.Cytology & HPV 30 F,35
F - 4,5,6,7 rounds
.Cytology 30 F - 5y
.Vaccination (12 F) +
Cytology 30 F - 5y
.Cytology 25 F/M - 3y +
HVP triage
.Vaccination (12 F) +
Cytology 25 F/M - 3y +
HVP triage
.Cytology 25 F/M - 2y +
HVP triage
.Vaccination 12 F/M +
Cytology 25 F/M - 3y +
HVP triage
.Vaccination 12 F +
Cytology 25 F/M - 2y
+ HVP triage
.Vaccination 12 F/M +
Cytology 25 F/M - 2y
+ HVP triage
Results ICER/QALY gained,
reductions in
cervical cancer
ICER/QALY gained,
reductions in
cervical cancer
ICER/QALY gained,
cervical cancer cases
and cervical cancer
deaths avoid
ICER/QALY gained,
cervical cancer cases
and cervical cancer
deaths avoid
ICER/QALY gained,
Kim, Ortendahl 2009 [34] Accetta 2010 [38] Diaz 2010 [43] Demarteau 2011 [41] Burger 2012 [42]
Strategy assessed .Cytology + HPV triage
lifetime for 35 F every
1y, 2y, 3y, 4y
.Cytology + HPV triage +
Combined cytology/HPV
after 35 F every 1y, 2y, 3y, 4y
.Cytology + HPV triage
lifetime for 45 F every
1y, 2y, 3y, 4y
.No intervention
.Cytology 25 F - 3y
.Cytology 25 F - 5y
.HPV DNA 25 F - 3y
.HPV DNA 25 F - 5y
.Cytology 25 F - 3y +
HPV triage
.Cytology 25 F - 5y +
HPV triage
.Cytology alone
.Cytology with HPV
triage
.Combined cytology
and HPV
.Vaccination + cytology
alone
.Vaccination + cytology
with HPV triage
.Cytology ?F – 3y
.Vaccination (12 F) +
Cytology ?F – 3y
(.Cytology ?F – 1y
.Vaccination (12 F) +
Cytology ?F – 1y
.Cytology ?F – 5y
.Vaccination (12 F) +
Cytology ?F – 5y)
.No vaccinated
.Vaccinated only (12 F)
.Screening frequency
3y to 6y, wait time for
rescreen 6 m or 12 m,
additional HPV+/Cyt-
1 to 3
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Table 7 Prevention strategies (Continued)
.Cytology + HPV triage +
Combined cytology/HPV
after 45 F every 1y, 2y, 3y, 4y
.HPV DNA 25 F - 3y +
Pap Triage
.HPV DNA 25 F - 5y +
Pap Triage
.Vaccination only (11 F)
.Vaccination (11 F) +
Cytology 25 F - 3y
.Vaccination (11 F) +
Cytology 25 F - 5y
.Vaccination (11 F) +
HPV DNA 25 F - 3y
.Vaccination (11 F) +
HPV DNA 25 F - 5y
.Vaccination (11 F) +
Cytology 25 F - 3y +
HPV triage
.Vaccination (11 F) +
Cytology 25 F - 5y +
HPV triage
.Vaccination (11 F) +
HPV DNA 25 F - 3y +
Pap Triage
.Vaccination (11 F) +
HPV DNA 25 F - 5y +
Pap Triage
.Vaccination + combined
cytology and HPV
Results ICER/QALY gained,
reductions in lifetime
risk of cervical cancer
ICER/life year gained,
lifetime risk of cervical
cancer, reduction in
cancer risk, cervical
cancer mortality
ICER/life year gained,
reduction in cervical
cancer
ICER/QALY gained ICER/life year gained,
reduction in
cancer
Coupe 2012 [37] Tully 2012 [40] Berkhof 2013 [44]
Strategy assessed .Cytology 30 F - 5y
.Vaccination only
.Vaccination + Cytology 30
F-7 times
.Vaccination + Cytology 30
F-6 times
.Vaccination + Cytology 30
F-5 times
.Vaccination + Cytology 30
F-4 times
.Vaccination + HPV DNA
screening-7 times +
cytological triage
.Vaccination + HPV DNA
screening-6 times +
cytological triage
.Vaccination + HPV DNA
screening-5 times +
cytological triage
.Vaccination + HPV DNA
screening-4 times +
cytological triage
.Vaccination (12 F) +
Cytology 21 F
.Vaccination (12 F) +
Cytology 25 F
.Vaccination only (12 F)
.10,6,3-yearly Pap
.10,6,3-yearly HPV
.Vaccination (12 F)
+10-yearly Pap
.Vaccination (12 F)
+10-yearly HPV
.Vaccination (12 F)
+6-yearly Pap
.Vaccination (12 F)
+6-yearly HPV
Results ICER/QALY gained, cancer
cases and deaths
ICER/QALY gained,
ICER/life year gained
ICER/QALY gained
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